ArriVent BioPharma
AVBP
16.89
+1.80
+11.93%
ArriVent BioPharma
US · AVBP
#3057 by market cap
Listed 2024
16.89
+1.80
+11.93%
Live - 5344 symbols - heartbeat 237s ago
· 2026-10-08 07:24
Pre-market
16.74
-0.88%
After-hours
17.10
+1.24%
Overnight
16.89
0.00%
- Market cap
- 832.81M
- P/E (TTM)i
- -4.76
- P/Bi
- 2.27
- EPSi
- -4.32
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on AVBP?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 8 analysts
Buy
Avg price target
44.57 +163.9%
Price target rangecurrent 16.89
Low40.00
Avg44.57
High50.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-15 | Truist Financial | -- | BUY | -- |
| 2026-09-15 | Guggenheim | -- | BUY | 45.00 |
| 2026-09-14 | LifeSci Capital | -- | BUY | 43.00 |
| 2026-09-14 | Citi | -- | BUY | 40.00 |
| 2026-08-17 | H.C. Wainwright | -- | BUY | 47.00 |
| 2026-08-14 | Citi | -- | BUY | 40.00 |
| 2026-08-13 | LifeSci Capital | -- | BUY | 43.00 |
| 2026-08-13 | Guggenheim | -- | BUY | 45.00 |
| 2026-08-13 | Oppenheimer | -- | BUY | 50.00 |
| 2026-08-12 | JonesTrading | -- | BUY | 45.00 |
| 2026-08-12 | BTIG | -- | BUY | 42.00 |
| 2026-07-22 | Guggenheim | -- | BUY | 45.00 |
| 2026-07-14 | LifeSci Capital | -- | BUY | 42.00 |
| 2026-07-14 | BTIG | -- | BUY | 42.00 |
| 2026-07-06 | JonesTrading | -- | BUY | 45.00 |
| 2026-06-04 | JonesTrading | -- | BUY | 45.00 |
| 2026-06-03 | Citi | -- | BUY | 43.00 |
| 2026-06-01 | Guggenheim | -- | BUY | 45.00 |
| 2026-06-01 | Oppenheimer | -- | BUY | 50.00 |
| 2026-05-29 | BTIG | -- | BUY | 42.00 |
| 2026-05-29 | B. Riley Securities | -- | BUY | 45.00 |
| 2026-05-19 | B. Riley Securities | -- | BUY | 45.00 |
| 2026-05-16 | LifeSci Capital | -- | BUY | 42.00 |
| 2026-05-13 | Citi | -- | BUY | 43.00 |
| 2026-05-13 | Oppenheimer | -- | BUY | 50.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 07:24:58 · For reference only, not investment advice and not tailored to your situation.